OncoPharm

The often encountered, seldom studied Elderly AML demographic is discussed in light of recent FDA approvals for glasdegib (new drug) and venetoclax (new indication). Then, (17:30) we discuss the 2nd drug "tissue agnostic" FDA approval by delving into NTRK-fusion-gene tumors and larotrectinib.

Describing the rationale for and rise in widespread ESA use for cancer patients going back 30 years....and why their use has been drastically curtailed in the last decade.

Discussing one of the main workhorse #oncopharm agents: cyclophosphamide. Topics include is bioactivation, myriad of uses, toxicity (hemorrhagic cystits) prevention and management.

Reviewing the latest TKI approved for ALK rearranged metastatic NSCLC. And hey, how 'bout that crazy rifampin hepatotoxicity interaction?

Running through recent notable updates on pembrolizumab, olaparib, atezolizumab, palbociclib and 5F9's introduction.

Discussing the scant evidence regarding influenza vaccination in cancer patients receiving immunotherapy. Warning! - unpublished abstracts are discussed by a guy with laryngitis.

Explore the recent FDA approval of talazoparib, a cutting-edge PARP inhibitor for breast cancer patients with BRCA mutations. Delve into its unique mechanism of action and effectiveness in comparison to olaparib. Understand key clinical considerations that doctors and patients should be aware of when choosing treatments. This discussion highlights advancements in cancer therapy and their implications for patient care.

The Landmarks in Oncology Pharmacy series returns with the P1 study. We review this landmark paper paving the way for breast cancer risk reduction (or chemoprevention) and discuss the mark or lack thereof (frown emoji) it has made in clinical practice.

Dacomitinib & cemiplimab's respective FDA-approvals are discussed followed by a lightning-round review of 4 immunotherapy studies from the last week. We end with dosing updates for 2 multiple myeloma drugs.

The latest #oncopharm approval for duvelisib is discussed as well as the similarities and differences to other PI3K inhibitors previously approved.